CN107090009B - 一种二糖核苷化合物及其制备方法 - Google Patents
一种二糖核苷化合物及其制备方法 Download PDFInfo
- Publication number
- CN107090009B CN107090009B CN201710244432.0A CN201710244432A CN107090009B CN 107090009 B CN107090009 B CN 107090009B CN 201710244432 A CN201710244432 A CN 201710244432A CN 107090009 B CN107090009 B CN 107090009B
- Authority
- CN
- China
- Prior art keywords
- added
- structural formula
- compound
- dissolved
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- -1 disaccharides nucleoside compound Chemical class 0.000 title claims abstract description 20
- 239000002777 nucleoside Substances 0.000 title claims abstract description 18
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 150000001875 compounds Chemical class 0.000 claims abstract description 42
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims abstract description 28
- 239000000203 mixture Substances 0.000 claims description 37
- 238000006243 chemical reaction Methods 0.000 claims description 33
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 20
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 20
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 20
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 18
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 18
- 150000008223 ribosides Chemical class 0.000 claims description 17
- 239000002131 composite material Substances 0.000 claims description 14
- 239000002904 solvent Substances 0.000 claims description 14
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 10
- 229910052757 nitrogen Inorganic materials 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 9
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 9
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 9
- 230000001681 protective effect Effects 0.000 claims description 8
- VQKFNUFAXTZWDK-UHFFFAOYSA-N 2-Methylfuran Chemical compound CC1=CC=CO1 VQKFNUFAXTZWDK-UHFFFAOYSA-N 0.000 claims description 6
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims description 6
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 239000012044 organic layer Substances 0.000 claims description 6
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 claims description 6
- 239000000047 product Substances 0.000 claims description 6
- 238000000926 separation method Methods 0.000 claims description 6
- 238000004809 thin layer chromatography Methods 0.000 claims description 6
- CHIHQLCVLOXUJW-UHFFFAOYSA-N benzoic anhydride Chemical compound C=1C=CC=CC=1C(=O)OC(=O)C1=CC=CC=C1 CHIHQLCVLOXUJW-UHFFFAOYSA-N 0.000 claims description 5
- 239000007791 liquid phase Substances 0.000 claims description 5
- 239000000460 chlorine Substances 0.000 claims description 4
- 239000012264 purified product Substances 0.000 claims description 4
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 claims description 3
- MCTWTZJPVLRJOU-UHFFFAOYSA-N 1-methyl-1H-imidazole Chemical compound CN1C=CN=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 claims description 3
- 229960000549 4-dimethylaminophenol Drugs 0.000 claims description 3
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 claims description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 3
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 claims description 3
- 229910052801 chlorine Inorganic materials 0.000 claims description 3
- 238000004440 column chromatography Methods 0.000 claims description 3
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 3
- 150000002460 imidazoles Chemical class 0.000 claims description 3
- ZVVSSOQAYNYNPP-UHFFFAOYSA-N olaflur Chemical compound F.F.CCCCCCCCCCCCCCCCCCN(CCO)CCCN(CCO)CCO ZVVSSOQAYNYNPP-UHFFFAOYSA-N 0.000 claims description 3
- 229960001245 olaflur Drugs 0.000 claims description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 3
- MHYGQXWCZAYSLJ-UHFFFAOYSA-N tert-butyl-chloro-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](Cl)(C(C)(C)C)C1=CC=CC=C1 MHYGQXWCZAYSLJ-UHFFFAOYSA-N 0.000 claims description 3
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 3
- 229940104230 thymidine Drugs 0.000 claims description 3
- 150000003852 triazoles Chemical class 0.000 claims description 3
- 108091028664 Ribonucleotide Proteins 0.000 claims description 2
- 238000012544 monitoring process Methods 0.000 claims description 2
- 238000005191 phase separation Methods 0.000 claims description 2
- 238000000746 purification Methods 0.000 claims description 2
- 239000002336 ribonucleotide Substances 0.000 claims description 2
- 125000002652 ribonucleotide group Chemical group 0.000 claims description 2
- 150000001408 amides Chemical class 0.000 claims 1
- SLLGVCUQYRMELA-UHFFFAOYSA-N chlorosilicon Chemical compound Cl[Si] SLLGVCUQYRMELA-UHFFFAOYSA-N 0.000 claims 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 abstract description 26
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 abstract description 26
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 abstract description 24
- 125000000623 heterocyclic group Chemical group 0.000 abstract description 6
- 125000001424 substituent group Chemical group 0.000 abstract description 3
- 239000000243 solution Substances 0.000 description 15
- 238000010586 diagram Methods 0.000 description 13
- 238000000034 method Methods 0.000 description 8
- 238000010898 silica gel chromatography Methods 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 125000002252 acyl group Chemical group 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 235000005979 Citrus limon Nutrition 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 125000004185 ester group Chemical group 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 238000006884 silylation reaction Methods 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- LCPVQAHEFVXVKT-UHFFFAOYSA-N 2-(2,4-difluorophenoxy)pyridin-3-amine Chemical compound NC1=CC=CN=C1OC1=CC=C(F)C=C1F LCPVQAHEFVXVKT-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- OGWXENANDYXVOY-UHFFFAOYSA-N C(CC)OP(N)N Chemical compound C(CC)OP(N)N OGWXENANDYXVOY-UHFFFAOYSA-N 0.000 description 1
- KWOGASBEHOQEPP-UHFFFAOYSA-N C[Si].[Cl] Chemical compound C[Si].[Cl] KWOGASBEHOQEPP-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 1
- 244000248349 Citrus limon Species 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 1
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000011260 aqueous acid Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003635 deoxygenating effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 150000002240 furans Chemical class 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 150000003290 ribose derivatives Chemical class 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- CHQMHPLRPQMAMX-UHFFFAOYSA-L sodium persulfate Substances [Na+].[Na+].[O-]S(=O)(=O)OOS([O-])(=O)=O CHQMHPLRPQMAMX-UHFFFAOYSA-L 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B53/00—Asymmetric syntheses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
- C07F7/1872—Preparation; Treatments not provided for in C07F7/20
- C07F7/188—Preparation; Treatments not provided for in C07F7/20 by reactions involving the formation of Si-O linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Saccharide Compounds (AREA)
Abstract
本发明公开了一种如通式1所示的二糖核苷化合物及其制备方法。所述化合物的结构通式如下:其中,第一核糖为2‑脱氧呋喃型核糖,第二核糖为呋喃型核糖,第一核糖与第二核糖之间由β构型相连;R1、R2、R3、R4、R5为不同的取代基团、R为杂环。
Description
技术领域
本发明涉及有机合成技术领域,尤其涉及一种二糖核苷化合物及其制备方法。
背景技术
二糖核苷是一类天然产物,从自然界已经分离出一百多种二糖核苷(E.V.Efimtseva,I.V.Kulikova,S.N.Mikhailov,Cur.Org.Chem.2007,11,337-354),它们具有抗细菌,杀虫,抗癌,抗病毒等活性(S.N.Mikhailov,E.V.Efimtseva.CollectionSymposium Series 2002,5,181-194),它们是tRNA和Poly(ADP-riboes)的片段(E.V.Efimtseva,S.N.Mikhailov,Biochemistry(Moscow),2002,67,1136-1144.),可以在核糖的代谢取代过程中生成(K.Uchida,Y.Suzuki,Biosci.Biotechnol.Biochem.2003,67,643-645.)。最近的研究表明,二糖核苷是潜在的PARPS的抑制剂,有可能成为治疗中风,糖尿病,关节炎等各类炎症,也可能是抗癌和抗病毒的药物(A.S.Efremova,A.L.Zakharenko,S.I.Shram,I.V.Kulikova,M.S.Drenichev,M.V.Sukhanova,S.N.Khodyreva,N.F.Myasoedov,O.I.Lavrik,S.N.Mikhailov,Nucleosides Nucleotides&Nucleic Acids,2013,32,510-528)。对二糖核苷合成方法的研究可以为发现PARP的抑制剂提供更多的机会。
另外,许多的抗病毒药物,例如HIV药物和HCV药物,都是核苷类化合物,若在它们的糖元部分上加上一个糖,与最初的药物相比,二糖核苷可以提高它们的水溶性及生物利用度,最终达到提高药效的目的(D.Benito,M.I.Matheu,A.Morere,Y.Diaz,S.Castillon,Carbohydr.Res.,2009,344,2559-2567)。因此,二糖核苷合成方法的研究,在药物研发这个领域将有广范的应用价值。
尽管许多新的合成二糖核苷的方法不断地被发现(Y.L.Zhang,S.Knapp.J.Org.Chem.,2016,81,2228–2242;A.Shin,F.Taketo;I.Taiki,K.Masayuki,S.Shigeto,K.Shin-ya,Chemistry–An Asian Journal,2015,10,740-751;E.V.Efimtseva,I.V.Kulikova,S.N Mikhailov,Molecular Biology,2009,43,301-312),但与2-去氧呋喃型核糖相关的二糖核苷的合成却未见报道。
因此,现有技术还有待发展。
发明内容
鉴于上述现有技术的不足之处,本发明的目的在于提供一种二糖核苷化合物及其制备方法,旨在为2-去氧呋喃型核糖相关的二糖核苷此类化合物的合成提供可行的方法。
为了达到上述目的,本发明采取了以下技术方案:
一种如通式1所示的二糖核苷化合物,
其中,第一核糖为2-脱氧呋喃型核糖,第二核糖为呋喃型核糖,第一核糖与第二核糖之间由β构型相连;R1、R2、R3、R4、R5为不同的取代基团、R为杂环。
所述的二糖核苷化合物,其中,所述R1、R2、R3、R4、R5分别为不同烷基,芳基,酰基,环烷基及磷酯基。
所述的二糖核苷化合物,其中,R2和R3为H,OH,F或CH3。
所述的二糖核苷化合物,其中,R1、R4、R5为烷基,芳基,酯基,硅烷基,磷脂基或酰基。
所述的二糖核苷化合物,其中,R为保护或者非保护的杂环类基团,与核糖的C1相连的为氮原子,硫原子,氧原子或碳原子。
一种结构通式1所示的二糖核苷化合物的制备方法,其中:
A、将胸腺嘧啶核苷溶解在吡啶中,加入咪唑和叔丁基二苯基氯硅烷,在保护气氛下反应完毕后,以预定的分离步骤获得结构式1所示的化合物;
B、将结构式1所示的化合物溶解在干燥的乙腈中,在保护气氛下,加入三乙胺和三甲基硅氯反应预定时间后,加入三氯氧磷和三氮唑并搅拌;反应完成后,加入水中止反应后,以预定的分离步骤获得结构式2所示的化合物;
C、将结构式2所示的化合物溶解于干燥的DMF中,加入苯甲酸酐,在保护气氛下反应完毕后,以预定的分离步骤获得结构式3所示的化合物;
D、将甲基呋喃型核糖核苷溶解于无水吡啶中,加入乙酸酐进行反应,反应完毕后,以预定的分离步骤获得结构式4所示的化合物;
E、将结构式4所示的化合物溶解于无水1,2-二氧乙烷中,加入SnCl4以及结构式3所示的化合物,在保护气氛下反应完毕后,以预定的分离步骤获得结构式5所示的混合物;所述混合物为一对端基差向异构体;
F、将结构式5所示的混合物溶解于四氢呋喃和甲醇混合液里,并加入碳酸钾搅拌反应完毕后,以预定的分离步骤获得结构式6所示的混合物;
G、将结构式6所示的混合物溶解于四氢呋喃并加入四丁基氟化胺,搅拌反应完毕后,以预定的分离步骤获得结构式7所示的混合物;
H、将结构式7所示的混合物溶解在干燥的吡啶中,加入DMAP和二对甲氧基苯基苯基甲基氯,搅拌反应完毕后,以预定的分离步骤获得DMT保护的二糖核苷端基差向异构体组成的混合物;
I、通过高压液相分离所述二糖核苷端基差向异构体组成的混合物,形成包含对应的,如结构式8所示的端基差向异构体的复合溶液1和复合溶液2;
J、分别对复合溶液1和复合溶液2进行处理,获得成品。
所述的制备方法,其中,所述预定的分离步骤具体包括:
在反应完毕后,去除反应体系的溶剂;
将反应体系内的残余物通过柱层析分离。
所述的制备方法,其中,所述步骤J具体包括:
分别将复合溶液1和复合溶液2在无水DMF中加入Bz2O,室温下搅拌过夜,分别获得如结构式9所示的端基差向异构化合物α和端基差向异构化合物β;
分别将端基差向异构化合物α和端基差向异构化合物β在四氢呋喃和甲醇的混合物中加入饱和碳酸钾溶液,室温下搅拌反应并通过薄层色谱监测;
去除溶剂后溶解在乙酸乙酯中,使用水冲洗有机层后,蒸发并对残留物通过HPLC纯化,分别获得包含如结构式10所示的端基差向异构化合物α和端基差向异构化合物β的纯化产物1和纯化产物2;
所述的制备方法,其中,所述步骤J具体包括:
将所述纯化产物1在DMF中共蒸发无水甲苯,其次在氮气和室温下加入tetraisopropylphosphorodiamidite和四唑,反应后加入N-甲基咪唑,在室温下搅拌过夜,经过高效液相色谱纯化获得如结构式11所示的xlvi-5-me-dc amidite;
所述的制备方法,其中,所述通过薄层色谱监测具体包括:添加pH为6的柠檬酸水溶液中和。
有益效果:本发明提供的制备方法可以合成单一2-去氧呋喃型核糖二糖核苷的方法,基于该单一2-去氧呋喃型核糖二糖核苷,可以进一步合成这一类的其它化合物,有利于相关药物的研究或者应用。
附图说明
图1为本发明实施例提供的步骤1的化学反应方程示意图;
图2为本发明实施例提供的步骤2的化学反应方程示意图;
图3为本发明实施例提供的步骤3的化学反应方程示意图;
图4为本发明实施例提供的步骤4的化学反应方程示意图;
图5为本发明实施例提供的步骤5的化学反应方程示意图;
图6为本发明实施例提供的步骤6的化学反应方程示意图;
图7为本发明实施例提供的步骤7的化学反应方程示意图;
图8为本发明实施例提供的步骤8的化学反应方程示意图;
图9为本发明实施例提供的步骤9-1的化学反应方程示意图;
图10为本发明实施例提供的步骤10-1的化学反应方程示意图;
图11为本发明实施例提供的步骤9-2的化学反应方程示意图;
图12为本发明实施例提供的步骤10-2的化学反应方程示意图;
图13为本发明实施例提供的步骤11的化学反应方程示意图;
图14为本发明实施例提供的二糖核苷化合物的结构通式。
具体实施方式
本发明提供一种二糖核苷化合物及其制备方法。为使本发明的目的、技术方案及效果更加清楚、明确,以下参照附图并举实施例对本发明进一步详细说明。应当理解,此处所描述的具体实施例仅用以解释本发明,并不用于限定本发明。
本发明实施例提供了一种如图14所示的二糖核苷化合物,其中,在图14所示的化合物通式中,第一核糖为2-脱氧呋喃型核糖,第二核糖为呋喃型核糖,第一核糖与第二核糖之间由β构型相连;R1、R2、R3、R4、R5为不同的取代基团、R为杂环,与第一核糖的C1碳连接。
可选地,通式1中的R1、R2、R3、R4、R5分别可以为不同烷基,芳基,酰基,环烷基及磷酯基。另外,通式1中的R可以是保护或者非保护的杂环类基团。R的杂环类集团中,与核糖的C1位置相连的可以为氮原子,硫原子,氧原子或碳原子。
在一些实施例中,R2和R3为H,OH,F或CH3中的一种。而R1、R4、R5为烷基,芳基,酯基,硅烷基,磷脂基或酰基中的一种。其中,R1、R2、R3、R4、R5均可以独立的选择。
通过以下实施例详细陈述上述通式1所示的化合物的合成制备过程。在实施例是图14的通式中其中一个化合物的合成过程。本领域技术人员可以根据实施例提供的详细合成步骤,通过改变使用的原料或者增加基团的取代、置换等步骤可以确定图14的通式所示的其它化合物的合成过程。
在本发明实施例提供的制备方法中,包括如下步骤:
1)将Thymidine溶在吡啶中,加入咪唑和叔丁基二苯基氯硅烷。上述反应物在氮气的保护下,搅拌12小时后,加水终止反应。最后,将溶剂蒸干,得到残余物经柱层析分离,得到化合物D1(如图1所示)。
2)将所述化合物D1溶于干燥的乙腈中,在-15℃,在氮气保护的反应条件下,加入三乙胺和三甲基硅氯,反应一小时。然后,在-15℃加入三氯氧磷和三氮唑,并搅拌2小时后,加入水中止反应(如图2所示)。
使用乙酸乙酯萃取,并用无水硫酸钠干燥有机层,减压蒸去溶剂后,将得到的残余物溶于1,4二氧六环和氨水的混合物,在氮水的保护下,室温搅拌12小时,减压蒸去溶剂后,用硅胶柱层析分离残余物(CH2Cl2:CH3OH=10:1),得到化合物D2。
3)将化合物D2溶于干燥的DMF中,加入苯甲酸酐。在氮气的保护下,室温搅拌2小时后,将溶剂蒸干,并使用乙酸乙酯溶解残余物。水洗后,用无水硫酸钠干燥,过滤,并将溶剂蒸干后通过硅胶柱层析,得到化合物D3(如图3所示)。
4)将甲基呋喃型核糖糖苷溶于干燥的无水吡啶中,加入乙酸酐,搅拌2小时后,将溶剂蒸干并用硅胶拄分离残余物,得到化合物D4(如图4所示)。
5)化合物D4溶于无水1,2-二氯乙烷,加入SnCl4,搅拌15分钟后,加入化合物D3,在0℃和氮气的保护下,搅拌2小时。然后,加入碳酸氢钠水溶液,用二氯甲烷萃取,有机层用无水硫酸钠干燥,过滤,将溶剂蒸干,残余物用硅胶柱层析分离,得到由一对端基差向异物体组成的混合物D5。这对端基差向异构体在各种分离条件下均很难以实现分离,在后续步骤中,直接对这对异构体进行处理(如图5所示)。
6)将混合物D5溶于四氢呋喃和甲醇混合液里,并加入碳酸钾,混合物在室温下搅拌一夜,将溶剂蒸干,残余物用硅胶柱层析分离,得到混合物D6。该混合物D6与混合物D5相类似的,也是由一对端基差向异构体组成(如图6所示)。
7)混合物D6溶于四氢呋喃中,并加入四丁基氟化胺,在室温下搅拌一夜。蒸干液体后,将残留物用硅胶柱层析分离。得到脱保护的二糖核苷的混合物D7(如图7所示)。
8)将混合物D7溶于干燥的吡啶中,加入DMAP和二对甲氧基苯基苯基甲基氯,在室温下搅拌4天,蒸去溶剂,残留物用硅胶柱层析分离,得到DMT保护的二糖核苷端基差向异构体的混合物(如图7所示)。此时,这对端基差向异构体可以通过高效液相制备分离,从而获得两个纯的端基差向异构体D8。
9-1)将其中一个端基差向异构体D8的复合溶液(1.4g,1.45mmol)在无水DMF中(9毫升)加入Bz2O(0.64克,2.9mmol)。该混合物在氮气下室温搅拌过夜(如图9所示)。
10-1)进一步将步骤9-1)获得的产物在四氢呋喃和甲醇的混合物(1:1,100毫升)加入80毫升饱和碳酸钾溶液。混合物在室温下搅拌反应,并用薄层色谱法进行监测。然后,除去溶剂,残留的溶解在乙酸乙酯(10毫升)中。有机层水冲洗(5毫升×2),蒸发,残渣进行HPLC纯化制备0.54克xlvi-5-me-dc PNS(如图10所示)。
在本步骤进行所述薄层色谱检测时,材料几乎消失,在一些实施例中,通过添加柠檬酸水溶液(pH=6)中和来解决材料消失,无法进行色谱检测的问题。
9-2)将另一个端基差向异构体D8的复合溶液(1.3g,1.35mmol)在无水DMF(9毫升)加入Bz2O(0.60克,2.7mmol)。该混合物在氮气下室温搅拌过夜(如图11所示)。
10-2)进一步将步骤9-2)获得的产物在四氢呋喃和甲醇的混合物(1:1,50毫升)加入80毫升饱和碳酸钾溶液。该混合物在室温下搅拌,并通过薄层色谱法监测。用乙酸乙酯(10毫升)溶解残留物,有机层用水冲洗(5毫升*2),浓缩,最后通过制备型高效液相色谱法对其进行纯化(如图12所示)。
与步骤10-1相类似的,存在进行所述薄层色谱检测时,材料几乎消失的问题。具体可以通过添加柠檬酸水溶液(pH=5)中和来解决材料消失,无法进行色谱检测的问题。
11)如图13所示,可以将在步骤10-1)中获得的xlvi-5-me-dc PNS溶液(200毫克,0.188毫摩尔)在DMF 1ml共蒸发无水甲苯(3毫升×2),然后在氮气和室温下加入tetraisopropylphosphorodiamidite(452毫克,1.5毫摩尔)和四唑(1.25毫升,0.45M的MeCN,0.56毫摩尔)。5分钟后,加入30μL的N-甲基咪唑,和混合物在室温下搅拌过夜。获得的粗产物经高效液相色谱纯化得到性状为白色泡沫的xlvi-5-me-dc amidite。(在本实施例中,最终获得成品150mg,收率为63%)。
可以理解的是,对本领域普通技术人员来说,可以根据本发明的技术方案及本发明构思加以等同替换或改变,而所有这些改变或替换都应属于本发明所附的权利要求的保护范围。
Claims (2)
1.一种二糖核苷化合物的制备方法,其特征在于:
A、将胸腺嘧啶核苷溶解在吡啶中,加入咪唑和叔丁基二苯基氯硅烷,在保护气氛下反应完毕后,以预定的分离步骤获得结构式1所示的化合物;
B、将结构式1所示的化合物溶解在干燥的乙腈中,在保护气氛下,加入三乙胺和三甲基硅氯反应预定时间后,加入三氯氧磷和三氮唑并搅拌;反应完成后,加入水中止反应后,以预定的分离步骤获得结构式2所示的化合物;
C、将结构式2所示的化合物溶解于干燥的DMF中,加入苯甲酸酐,在保护气氛下反应完毕后,以预定的分离步骤获得结构式3所示的化合物;
D、将甲基呋喃型核糖核苷溶解于无水吡啶中,加入乙酸酐进行反应,反应完毕后,以预定的分离步骤获得结构式4所示的化合物;
E、将结构式4所示的化合物溶解于无水1,2-二氧乙烷中,加入SnCl4以及结构式3所示的化合物,在保护气氛下反应完毕后,以预定的分离步骤获得结构式5所示的混合物;所述混合物为一对端基差向异构体;
F、将结构式5所示的混合物溶解于四氢呋喃和甲醇混合液里,并加入碳酸钾搅拌反应完毕后,以预定的分离步骤获得结构式6所示的混合物;
G、将结构式6所示的混合物溶解于四氢呋喃并加入四丁基氟化胺,搅拌反应完毕后,以预定的分离步骤获得结构式7所示的混合物;
H、将结构式7所示的混合物溶解在干燥的吡啶中,加入DMAP和二对甲氧基苯基苯基甲基氯,搅拌反应完毕后,以预定的分离步骤获得DMT保护的二糖核苷端基差向异构体组成的混合物;
I、通过高压液相分离所述二糖核苷端基差向异构体组成的混合物,形成包含对应的,如结构式8所示的端基差向异构体的复合溶液1和复合溶液2;
J、分别对复合溶液1和复合溶液2进行处理,获得成品;
所述步骤J具体包括:
分别将复合溶液1和复合溶液2在无水DMF中加入Bz2O,室温下搅拌过夜,分别获得如结构式9所示的端基差向异构化合物α和端基差向异构化合物β;
分别将端基差向异构化合物α和端基差向异构化合物β在四氢呋喃和甲醇的混合物中加入饱和碳酸钾溶液,室温下搅拌反应并通过薄层色谱监测;
去除溶剂后溶解在乙酸乙酯中,使用水冲洗有机层后,蒸发并对残留物通过HPLC纯化,分别获得包含如结构式10所示的端基差向异构化合物α和端基差向异构化合物β的纯化产物1和纯化产物2;
将所述纯化产物1在DMF中共蒸发无水甲苯,其次在氮气和室温下加入四异丙基磷酸二酰胺和四唑,反应后加入N-甲基咪唑,在室温下搅拌过夜,经过高效液相色谱纯化获得如结构式11所示的二糖核苷化合物;
所述预定的分离步骤具体包括:
在反应完毕后,去除反应体系的溶剂;
将反应体系内的残余物通过柱层析分离。
2.根据权利要求1所述的制备方法,其特征在于,所述通过薄层色谱监测具体包括:添加pH为6的柠檬酸水溶液中和。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710244432.0A CN107090009B (zh) | 2017-04-14 | 2017-04-14 | 一种二糖核苷化合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710244432.0A CN107090009B (zh) | 2017-04-14 | 2017-04-14 | 一种二糖核苷化合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107090009A CN107090009A (zh) | 2017-08-25 |
CN107090009B true CN107090009B (zh) | 2019-10-25 |
Family
ID=59637282
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710244432.0A Expired - Fee Related CN107090009B (zh) | 2017-04-14 | 2017-04-14 | 一种二糖核苷化合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107090009B (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101517082A (zh) * | 2006-09-27 | 2009-08-26 | 科勒制药有限责任公司 | 具有增强的免疫刺激活性的含疏水性T类似物的CpG寡聚核苷酸类似物 |
-
2017
- 2017-04-14 CN CN201710244432.0A patent/CN107090009B/zh not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101517082A (zh) * | 2006-09-27 | 2009-08-26 | 科勒制药有限责任公司 | 具有增强的免疫刺激活性的含疏水性T类似物的CpG寡聚核苷酸类似物 |
Non-Patent Citations (1)
Title |
---|
isaccharide Pyrimidine Nucleosides and Their Derivatives: A Novel Group of Cell-Penetrating Inhibitors of Poly(ADPRibose) Polymerase 1;Anna S. Efremova et al.;《Nucleosides, Nucleotides and Nucleic Acids》;20130930;第32卷;510-528 * |
Also Published As
Publication number | Publication date |
---|---|
CN107090009A (zh) | 2017-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ralph et al. | Studies on Polynucleotides. XI. 1 Chemical Polymerization of Mononucleotides. The Synthesis and Characterization of Deoxyadenosine Polynucleotides2 | |
CN103068834B (zh) | 用于反向合成rna的亚磷酰胺 | |
Mag et al. | Synthesis and selective cleavage of an oligodeoxynucleotide containing a bridged intemucleotide 5′-phosphorothioate linkage | |
Seela et al. | Palindromic oiigonucleotides containing 7-deaza-2'-deoxyguanosine: solid-phase synthesis of d [(p) GG* AATTCC] octamers and recognition by the endodeoxyribonnclease EcoRI | |
Ying et al. | General methods for the synthesis of glycopyranosyluronic acid azides | |
JP2001515086A5 (zh) | ||
Podvalnyy et al. | Ring opening of acylated β-d-arabinofuranose 1, 2, 5-orthobenzoates with nucleophiles allows access to novel selectively-protected arabinofuranose building blocks | |
Pozsgay | A new strategy in oligosaccharide synthesis using lipophilic protecting groups: synthesis of a tetracosasaccharide | |
Seela et al. | Solid-phase synthesis of the self-complementary hexamer d (c 7 GpCpc 7 GpCpc 7 GpC) via the O-3′-phosphoramidite of 7-deaza-2′-deoxyguanosine | |
Pal et al. | Chemical synthesis of the pentasaccharide repeating unit of the O-specific polysaccharide from Ruminococcus gnavus | |
Ohtsuka et al. | Studies on transfer ribonucleic acids and related compounds. 20. A new versatile ribooligonucleotide block with 2'-(o-nitrobenzyl) and 3'-phosphorodianilidate groups suitable for elongation of chains in the 3'and 5'directions | |
Castro-Pichel et al. | A facile synthesis of ascamycin and related analogues | |
Abronina et al. | A Practical Silicon-Free Strategy for Differentiation of Hydroxy Groups in Arabinofuranose Derivatives | |
Tiwari et al. | Acylation of carbohydrates over Al2O3: preparation of partially and fully acylated carbohydrate derivatives and acetylated glycosyl chlorides | |
CN102127135A (zh) | 一种嘧啶类核苷化合物或嘌呤类核苷化合物的制备方法 | |
González et al. | A facile chemoselective deacetylation in the presence of benzoyl and p-bromobenzoyl groups using p-toluenesulfonic acid | |
CN107090009B (zh) | 一种二糖核苷化合物及其制备方法 | |
Ishido et al. | Partial protection of carbohydrate derivatives. Part 4. Regioselective 2′-O-deacylation of fully acylated purine and pyrimidine ribonucleosides with hydroxylaminium acetate | |
Amiot et al. | New approach for the synthesis of c-di-GMP and its analogues | |
Reese | The H-phosphonate approach to the synthesis of oligonucleotides and their phosphorothioate analogues in solution | |
Kusmierek et al. | Synthesis of N2, 3-ethenodeoxyguanosine, N2, 3-ethenodeoxyguanosine 5'-phosphate, and N2, 3-ethenodeoxyguanosine 5'-triphosphate. Stability of the glycosyl bond in the monomer and in poly (dG,. epsilon. dG-dC) | |
La Ferla et al. | Synthesis of building blocks of human milk oligosaccharides. Fucosylated derivatives of the lacto-and neolacto-series | |
Zong et al. | Highly efficient removal of allyloxycarbonyl (Alloc) function provides a practical orthogonal protective strategy for carbohydrates | |
CN110615818B (zh) | 氟达拉滨和奈拉滨的合成方法 | |
Ramu Sridhar et al. | Chemistry of tetrathiomolybdate and tetraselenotungstate: Applications in carbohydrate chemistry |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20191025 |